Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EZH2 | Q15910 | 17/20 | 0.36 |
| ▸ | EED | O75530 | 5/20 | 0.35 |
| ▸ | SUZ12 | Q15022 | 5/20 | 0.35 |
| ▸ | RBBP4 | Q09028 | 4/20 | 0.35 |
| ▸ | AEBP2 | Q6ZN18 | 4/20 | 0.35 |
| ▸ | EZH1 | Q92800 | 3/20 | 0.34 |
| ▸ | RBBP7 | Q16576 | 1/20 | 0.32 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16549193 | 0.83 | EZH2 (0.43) | EZH2EEDSUZ12RBBP4AEBP2 | |
| SCHEMBL19430013 | 0.82 | AOC3 (0.37) | EZH2EZH1CHRM3 | |
| SCHEMBL12684098 | 0.82 | EZH2 (0.50) | EZH2EEDSUZ12RBBP4AEBP2 | |
| SCHEMBL19429904 | 0.79 | KLKB1 (0.39) | — | |
| SCHEMBL19429847 | 0.79 | HTT (0.37) | CHRM3 | |
| SCHEMBL19430208 | 0.79 | ACKR3 (0.39) | CHRM3 | |
| SCHEMBL19430060 | 0.78 | KMT2A (0.40) | — | |
| SCHEMBL19430021 | 0.78 | KMT2A (0.38) | CHRM3 | |
| SCHEMBL19430193 | 0.77 | AOC3 (0.37) | — | |
| SCHEMBL19429836 | 0.76 | AOC3 (0.35) | CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9637472-B2 | Substituted 6,5-fused bicyclic heteroaryl compounds | Epizyme, Inc. (US) | 2017-05-02 | — | — | US | disclosed |
| US-9637472-B2 | Substituted 6,5-fused bicyclic heteroaryl compounds | Epizyme, Inc. (US) | 2017-05-02 | — | — | US | disclosed |
| US-20150065483-A1 | Substituted 6,5-Fused Bicyclic Heteroaryl Compounds | Epizyme, Inc. | 2015-03-05 | — | — | US | disclosed |
| US-20150065483-A1 | Substituted 6,5-Fused Bicyclic Heteroaryl Compounds | Epizyme, Inc. | 2015-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150065483-A1 | Substituted 6,5-Fused Bicyclic Heteroaryl Compounds | CYP3A5, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CYP2D6 | EZH2 1355/4885EED 2585/4885SUZ12 1082/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.